Drugs / RAPA-501
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04482699 | Dec 2020 → Sep 2021 | COVID-19 | Rapa Therapeutics LLC | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04220190 | Jan 2025 → Jul 2026 overdue | amyotrophic lateral sclerosis | Rapa Therapeutics LLC | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RAPA-501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04482699 ↗ |
| Modality | Cell therapy | “RAPA-501 T stem cell therapy” NCT04220190 ↗ |